Melior Discovery about us
Founded in 2005, Melior Discovery has pioneered a unique, optimized, high throughput pharmacology platform that is able to systematically identify novel indications for pre-clinical and development stage drug candidates. Melior also applies this expertise to the provision of a range of essential pre-clinical and discovery services for clients in the pharmaceutical and biopharmaceutical industries, including pharmacokinetic evaluations, efficacy models and bioanalytical testing.
Melior’s theraTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently, over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. In most cases, Melior’s theraTRACE® system is able to provide a complete pharmacological profile of a compound in 10 weeks. theraTRACE® has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies.
In addition to the theraTRACE® indications discovery platform, Melior is able to extend its high throughput pharmacology approach to customized in vivo efficacy evaluations in other focused therapeutic areas. Melior has established expertise in the following major areas:
Melior’s management has combined experience of more than 120 years in pharmacology and drug discovery applications and has evaluated more than
600 compounds for novel indications in just 6 years. The company has long-term collaborations with Pfizer, Merck, AstraZeneca, Johnson and Johnson, amongst others major partners.
If you are interested in learning more about our team, please contact email@example.com to start the conversation.